期刊
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
卷 89, 期 2, 页码 106-111出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.diagmicrobio.2017.07.006
关键词
Middle East respiratory syndrome coronavirus; Prognosis; Antibody; Serologic response
资金
- Samsung Biomedical Research Institute (SBRI) [SMX11613211]
- EU grants Antigone (GA) [278976, 602525]
We evaluated serologic response of 42 Middle East respiratory syndrome coronavirus (MERS-CoV)-infected patients according to 4 severity groups: asymptomatic infection (Group 0), symptomatic infection without pneumonia (Group 1), pneumonia without respiratory failure (Group 2), and pneumonia progressing to respiratory failure (Group 3). None of the Group 0 patients showed seroconversion, while the seroconversion rate gradually increased with increasing disease severity (0.0%, 60.0%, 93.8%, and 100% in Group 0, 1, 2, 3, respectively; P = 0.001), Group 3 patients showed delayed increment of antibody titers during the fourth week, while Group 2 patients showed robust increment of antibody titer during the third week. Among patients having pneumonia, 75% of deceased patients did not show seroconversion by the third week, while 100% of the survived patients were seroconverted (P = 0.003). (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据